Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum

Pathophysiology of Placenta Accreta Clinical Trial

Official title:

Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04628169
• Other study ID #: netrin-1 in placenta accreta
• Status: Completed
• Start date: December 1, 2021
• Est. completion date: December 1, 2023

Study information

• Verified date: May 2024
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main goal of this study the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum. To delineate the role of netrin-1, neogenin - zeb1 signaling pathway in mechanism of morbidly adherent placenta.

Description:

The main goal of this study is: - To shed light on the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum. - To study the role of netrin-1 in Epithelial to mesenchymal transition as a possible pathophysiological mechanism of placenta accrete spectrum. - To delineate the role of netrin-1, neogenin - zeb1 signaling pathway in the progression of invasion of placenta accrete spectrum.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 1, 2023
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• ages between 20 to 40 years will be included.
• Gestational age: between 34 to 38 weeks.
• History of previous cesarean sections. suspected intra-operative abnormal placental adhesion of variable degrees Exclusion Criteria: Fundal and middle anterior or posterior placenta.
• Pregnancy associated with morbid conditions as: hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, and endocrinal disease.

Related Conditions & MeSH terms

• Pathophysiology of Placenta Accreta
• Placenta Accreta

Locations

Country	Name	City	State
Egypt	Hanaa Mohammed Mohammed Sayed	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	impact of netrin-1 in the pathophysiology of placenta accreta spectrum	Estimation of local placental netrin-1 protein expression by immunohistochemistry , Estimation of local placental expression of neognin by immunohistochemistry. Estimation of local placental expression of Zeb-1 by immunohistochemistry	baseline